Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, et al. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. Targeted oncology. 2024
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, et al. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma. Cancer reports (Hoboken, N.J.). 2024. 7. 4. e2042
Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Fabian Finkelmeier, Changhoon Yoo, José Presa, Elisabeth Amadeo, et al. Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab. Liver international : official journal of the International Association for the Study of the Liver. 2024
Tyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih-Wen Wang, Man-Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, et al. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study. Journal of gastroenterology and hepatology. 2024
Hidenori Toyoda, Toshifumi Tada, Haruki Uojima, Akito Nozaki, Makoto Chuma, Koichi Takaguchi, Atsushi Hiraoka, Hiroshi Abe, Ei Itobayashi, Kentaro Matsuura, et al. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology. 2024